fbPfizer Inc. Technical Analysis | Pfizer Inc. Trading: 2022-06-21 | IFCM UK
IFC Markets Online CFD Broker

Pfizer Inc. Technical Analysis - Pfizer Inc. Trading: 2022-06-21

Pfizer Inc. Technical Analysis Summary

Accelerometer arrow
Strong SellSellNeutralBuyStrong Buy

Below 46.26

Sell Stop

Above 50.40

Stop Loss

Ara Zohrabian
Senior Analytical Expert
Articles 2110
IndicatorSignal
RSI Buy
MACD Sell
Donchian Channel Sell
MA(200) Sell
Fractals Sell
Parabolic SAR Sell

Pfizer Inc. Chart Analysis

Pfizer Inc. Chart Analysis

Pfizer Inc. Technical Analysis

The technical analysis of the Pfizer stock price chart on daily timeframe shows #S-PFE,Daily is retracing under the 200-day moving average MA(200) which has levelled off. RSI is in oversold zone. We believe the bearish momentum will continue after the price breaches below the lower boundary of Donchian channel at 46.26. This level can be used as an entry point for placing a pending order to sell. The stop loss can be placed at 50.40. After placing the order, the stop loss is to be moved every day to the next fractal high, following Parabolic signals. Thus, we are changing the expected profit/loss ratio to the breakeven point. If the price meets the stop loss level (50.40) without reaching the order (46.26), we recommend cancelling the order: the market has undergone internal changes which were not taken into account.

Fundamental Analysis of Stocks - Pfizer Inc.

Pfizer is buying stake in French vaccine maker Valneva. Will the Pfizer stock price rebound?

Pfizer has agreed to pay €90.5mn for an 8.1% stake in Valneva, in a move that will bolster the French vaccine company’s Lyme disease program. Pfizer is buying the stake at a price of €9.49 a share — a 20% premium to Valneva’s closing price on Friday of €7.94. The proceeds from the transaction disclosed on Monday will go towards developing a Lyme disease joint program. Valneva will fund 40% of the remaining shared development costs, Pfizer will pay Valneva tiered royalties from 14% to 22%, which will be complemented by up to $100 million in payments to Valneva if certain sales milestones are reached. There is currently no vaccine available for Lyme disease, a tick-borne infection that can prove seriously debilitating. Expectations of rising sales are bullish for company’s stock price. However the current setup is bearish for the stock.

Trading signals with a probability of 80% by Autochartist

  • Easy to use
  • Fully automatic
  • Wide range of analytics

The best trading conditions and high-level services for our clients

We are ready to assist you on any issue 24 hours a day.

Note:
This overview has an informative and tutorial character and is published for free. All the data, included in the overview, are received from public sources, recognized as more or less reliable. Moreover, there is no guarantee that the indicated information is full and precise. Overviews are not updated. The whole information in each overview, including opinion, indicators, charts and anything else, is provided only for familiarization purposes and is not financial advice or а recommendation. The whole text and its any part, as well as the charts cannot be considered as an offer to make a deal with any asset. IFC Markets and its employees under any circumstances are not liable for any action taken by someone else during or after reading the overview.